These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36494733)

  • 1. Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case study.
    Abdallah K; Claes K; Huys I; Follon L; Calis C; Simoens S
    Orphanet J Rare Dis; 2022 Dec; 17(1):429. PubMed ID: 36494733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical assessment of belgian reimbursement dossiers of orphan drugs.
    Denis A; Mergaert L; Fostier C; Cleemput I; Hulstaert F; Simoens S
    Pharmacoeconomics; 2011 Oct; 29(10):883-93. PubMed ID: 21905759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Off-label use of orphan medicinal products: a Belgian qualitative study.
    Dooms M; Cassiman D; Simoens S
    Orphanet J Rare Dis; 2016 Oct; 11(1):144. PubMed ID: 27793155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Orphan diseases and orphan medicines: a Belgian and European study].
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [FINANCING OF MEDICINES FOR TREATMENT OF RARE DISEASES OF THE NERVOUS SYSTEM. ORPHAN DRUGS IN RARE NEUROLOGICAL DISEASES].
    Szegedi Márta ; Kosztolányi G; Boncz I; Molnár MJ
    Ideggyogy Sz; 2016 Jan; 69(1-2):37-45. PubMed ID: 26987239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
    Hughes-Wilson W; Palma A; Schuurman A; Simoens S
    Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Shift of focus in the financing of Hungarian drugs. Reimbursement for orphan drugs for treating rare diseases: financing of enzyme replacement therapy in Hungary].
    Szegedi M; Molnár MJ; Boncz I; Kosztolányi G
    Orv Hetil; 2014 Nov; 155(44):1735-41. PubMed ID: 25344850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016.
    Löblová O; Csanádi M; Ozierański P; Kaló Z; King L; McKee M
    Health Policy; 2019 Aug; 123(8):713-720. PubMed ID: 31277882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
    Zelei T; Molnár MJ; Szegedi M; Kaló Z
    Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reimbursement of orphan drugs in Belgium: what (else) matters?
    Picavet E; Cassiman D; Simoens S
    Orphanet J Rare Dis; 2014 Sep; 9():139. PubMed ID: 25208770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?
    Kanters TA; Hakkaart L; Rutten-van Mölken MP; Redekop WK
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):557-9. PubMed ID: 25973903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access to orphan drugs in Europe: current and future issues.
    Michel M; Toumi M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Orphan drugs: availability, reliability and reimbursement].
    Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
    Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Access to orphan drugs despite poor quality of clinical evidence.
    Dupont AG; Van Wilder PB
    Br J Clin Pharmacol; 2011 Apr; 71(4):488-96. PubMed ID: 21395641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient access to orphan drugs in France.
    Bourdoncle M; Juillard-Condat B; Taboulet F
    Orphanet J Rare Dis; 2019 Feb; 14(1):47. PubMed ID: 30777102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology.
    Löblová O; Csanádi M; Ozierański P; Kaló Z; King L; McKee M
    Health Policy; 2019 Jul; 123(7):630-634. PubMed ID: 31130319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu.
    Zhang X; Zhou T; Zhou J; Zhang D; Yang Y; Pan J
    BMC Health Serv Res; 2024 Sep; 24(1):1123. PubMed ID: 39334210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient Access to Orphan Drugs Covered by Medical Insurance in China: Real-World Evidence From Patient Survey.
    Wang X; Li SC; Yue X; Li Y; Shi N; Zhao FL; Wu J
    Value Health Reg Issues; 2023 Mar; 34():71-77. PubMed ID: 36587572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.